Effects of Inhaled Aviptadil (Vasoactive Intestinal Peptide) in Patients With Pulmonary Arterial Hypertension (PAH)

doi 10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a2516
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Thoracic Society

Related search

Inhalation of Vasoactive Intestinal Peptide in Pulmonary Hypertension

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2008English

P2 In-Flight Hypoxaemia in Patients With Pulmonary Arterial Hypertension (PAH)

Thorax
PulmonaryRespiratory Medicine
2011English

Pulmonary Clearance of Vasoactive Intestinal Peptide.

Thorax
PulmonaryRespiratory Medicine
1986English

Rapid Transition From Inhaled Iloprost to Inhaled Treprostinil in Patients With Pulmonary Arterial Hypertension

Cardiovascular Therapeutics
MedicineCardiovascular MedicinePharmacologyCardiology
2013English

Tolerability and Clinical Efficacy of Inhaled Treprostinil in Patients With Group 1 Pulmonary Arterial Hypertension

Therapeutic Advances in Chronic Disease
Medicine
2018English

Withdrawal of Long-Term Epoprostenol Therapy in Pulmonary Arterial Hypertension (PAH)

Pulmonary Circulation
PulmonaryRespiratory Medicine
2017English

Inhaled Iloprost for Treatment of Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2002English

Development of a New Patient-Reported Outcome (PRO) Instrument for Pulmonary Arterial Hypertension (PAH): The Pulmonary Arterial Hypertension–symptoms and Impact (PAH-SYMPACT) Questionnaire

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Characterizing Patients Treated With Macitentan for Pulmonary Arterial Hypertension (PAH) in the U.S. Opsumit Users Registry (OPUS)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy